Cardiology Department, Coimbra University Hospital and Medical School, Coimbra, Portugal.
Eur J Clin Pharmacol. 2010 Mar;66(3):219-30. doi: 10.1007/s00228-009-0764-y. Epub 2009 Dec 10.
The role of vascular endothelium in cardiovascular disorders is well recognized. Mature endothelial cells contribute to the repair of endothelial injury, but they only have a limited capacity to do so. This has led to growing interest and further investigation into circulating endothelial progenitor cells (EPCs) and their role in vascular healing, repair, and postnatal neovascularization. The current perception of vascular health is that of a balance between ongoing injury and resultant vascular repair, mediated at least in part by circulating EPCs. Circulating EPCs play an important role in accelerating endothelialization at areas of vascular damage, and EPC enumeration is a viable strategy for assessing reparative capacity. Recent studies have shown that EPCs are affected both in number and function by several cardiovascular risk factors as well as various cardiovascular disease states, such as hypertension, hypercholesterolemia, and coronary artery disease. The present review summarizes the most relevant studies on the effects of cardiovascular drugs on vascular function and EPCs, focusing on their mechanisms of action.
血管内皮细胞在心血管疾病中的作用已得到充分认识。成熟的内皮细胞有助于修复内皮损伤,但它们的修复能力有限。这使得人们对循环内皮祖细胞(EPC)及其在血管愈合、修复和出生后血管新生中的作用产生了越来越大的兴趣和进一步的研究。目前对血管健康的认识是,在持续的损伤和由此产生的血管修复之间保持平衡,至少部分是由循环 EPC 介导的。循环 EPC 在加速血管损伤部位的内皮化方面发挥着重要作用,EPC 计数是评估修复能力的可行策略。最近的研究表明,多种心血管危险因素和各种心血管疾病状态,如高血压、高胆固醇血症和冠心病,都会影响 EPC 的数量和功能。本综述总结了关于心血管药物对血管功能和 EPC 影响的最相关研究,重点介绍了它们的作用机制。